FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

View source ↗

Summary

FDA approves Rasonque (daraxonrasib), a first-in-class RAS inhibitor, for metastatic pancreatic cancer, marking a novel targeted therapy option in this indicati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Rasonque (daraxonrasib)

Snippet

The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.